Sleep and Circadian Rhythms in Alzheimer Disease: Potential bi-directional relationship with tau
Sleep and Circadian Rhythms in Alzheimer Disease: Potential bi-directional relationship with tau
批准号:
9815588
负责人:
DAVID M. HOLTZMAN
金额:
$369.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-15 至 2024-06-30
关键词:
ARNTL geneAcuteAffectAlzheimer&aposs DiseaseAlzheimer&aposs disease riskAmyloidAmyloid beta-ProteinApolipoprotein EAppearanceBehaviorBiological MarkersBrainBrain DiseasesChronicCircadian DysregulationCircadian RhythmsCognitiveDataDepositionDiseaseDiurnal RhythmEventExhibitsFunctional disorderFutureGeneticGenotypeHourHumanImpaired cognitionIndividualInjectionsIntercellular FluidKnock-in MouseLinkMeasurementMediatingMemory LossModelingMusNerve DegenerationNeuronsParticipantPathogenesisPathologicPathologyPeptidesPharmacologyPhasePolysomnographyPreventive InterventionPreventive therapyProcessProteinsRegulationRiskRoleSeedsSenile PlaquesSleepSleep DeprivationSleep Wake CycleSleep disturbancesSynapsesSystemTauopathiesTranscriptWild Type Mouseactigraphyamyloid formationbasecircadiancircadian pacemakercohortcommon symptomdesignexperimental studyhypocretinin vivomouse modelneuroinflammationnew technologynon-geneticpre-clinicaltau Proteinstau aggregation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Sleep and Circadian Rhythms in Alzhiemer’s Disease: Potential bi-directional relationship with tau
Sleep and circadian rhythm disturbances have long been described in symptomatic Alzheimer’s Disease (AD).
Recent studies by our group and others show that these disturbances are detectable years before the onset of
cognitive impairment, during the preclinical phase of AD. Our group has shown that modulating the amount of
sleep in mice has striking effects on amyloid plaque deposition, as sleep deprivation augments plaque burden
while sleep enhancement reduces plaques. Moreover, we have found that levels of Aβ peptide in the
interstitial fluid (ISF) exhibit clear diurnal rhythms which are regulated by the sleep/wake cycle and the central
circadian clock, and that disruption of the circadian system and promotes amyloid plaque formation. While
amyloid plaque deposition is the first known biomarker change in AD, it appears to be the ability of amyloid
plaques to augment tau aggregation and spreading that is directly linked to neurodegeneration and cognitive
decline in AD. Tau spreading though the brain, and the effect of Aβ pathology on tau aggregation, can be
modeled by injection of tau-enriched AD brain lysate into the brain of Aβ plaque-bearing APP knock-in mice.
Based on our preliminary data, we hypothesize that sleep disturbance and circadian rhythm disruption may
promote tau spreading and aggregation by increasing the release of tau seeding species from neurons. We
propose to examine the impact of chronically restricting or increasing sleep on neuronal tau spreading and
plaque-induced tau aggregation in mice. Because apolipoprotein E (apoE) strongly influence Aβ and tau
pathology and interacts with sleep, we will elucidate the interaction between APOE genotype, sleep
deprivation, and tau spreading and aggregation. Using both genetic and environmental circadian disruption
models, we will perform similar experiments to determine the effects of circadian disruption on tau spreading
and Aβ-induced tau aggregation, and explore the interplay between circadian disruption, sleep, and apoE on
Aβ and tau pathology. Finally, we will examine the longitudinal relationship between sleep disturbance,
circadian fragmentation, and preclinical Aβ and tau pathology in humans. We hypothesize a bidirectional
relationship between AD pathology and sleep/circadian rhythms, in which AD pathology disrupts
sleep/circadian function, while sleep/circadian disruption promotes AD pathology. We will if sleep or circadian
rhythm changes are associated with increased future risk of plaque deposition, tau aggregation, or cognitive
decline in humans. These studies will elucidate the interaction between sleep, circadian rhythms, and tau
aggregation in mice and humans, as well as the role of apoE in that process.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cerebral amyloid angiopathy: Role of ApoE, innate immunity, and meningeal lymphatics
-
批准号:10674679
-
项目类别:
-
资助金额:$62.0万
-
财政年份:2022
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
APOE effects on glial lipid metabolism and 25-hydroxycholesterol: Effects on aging and AD-related pathology
-
批准号:10667466
-
项目类别:
-
资助金额:$53.02万
-
财政年份:2021
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
APOE effects on glial lipid metabolism and 25-hydroxycholesterol: Effects on aging and AD-related pathology
-
批准号:10407944
-
项目类别:
-
资助金额:$54.01万
-
财政年份:2021
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Administration Core
-
批准号:10622634
-
项目类别:
-
资助金额:$80.27万
-
财政年份:2020
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Alzheimer's Disease Research Center
-
批准号:10622633
-
项目类别:
-
资助金额:$307.63万
-
财政年份:2020
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Nervous System Development and Injury
-
批准号:9386458
-
项目类别:
-
资助金额:$0.83万
-
财政年份:2016
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Novel Strategies and Mechanisms to Target APOE and Alzheimer's Disease
-
批准号:8779836
-
项目类别:
-
资助金额:$59.46万
-
财政年份:2014
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Novel Strategies and Mechanisms to Target APOE and Alzheimer's Disease
-
批准号:9060227
-
项目类别:
-
资助金额:$55.3万
-
财政年份:2014
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Novel Strategies and Mechanisms to Target APOE and Alzheimer's Disease
-
批准号:9814735
-
项目类别:
-
资助金额:$376.01万
-
财政年份:2014
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Administrative Core
-
批准号:10006905
-
项目类别:
-
资助金额:$7.01万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8642679
-
项目类别:
-
资助金额:$112.94万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Dynamic Regulation of Amyloid-^ in the CNS
-
批准号:8331629
-
项目类别:
-
资助金额:$29.84万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8838268
-
项目类别:
-
资助金额:$112.94万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Effects of the Sleep/Wake Cycle on A-Beta, Tau and Spreading
-
批准号:10006907
-
项目类别:
-
资助金额:$38.27万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Neuronal LRP1 and HSPG in Pathological Spreading of A-Beta and Tau
-
批准号:10246278
-
项目类别:
-
资助金额:$39.36万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Administrative Core
-
批准号:10246274
-
项目类别:
-
资助金额:$6.79万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Neuronal LRP1 and HSPG in Pathological Spreading of A-Beta and Tau
-
批准号:10006909
-
项目类别:
-
资助金额:$39.91万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8467068
-
项目类别:
-
资助金额:$110.69万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synaptic, Cellular Modulation of Abeta Metabolism
-
批准号:9764499
-
项目类别:
-
资助金额:$146.62万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8268731
-
项目类别:
-
资助金额:$116.73万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
海外基金